Rolling Out3d
What are my treatment options for kidney failure?
Advanced treatments for kidney failure offers patients improved survival rates and quality of life. Discover the options from ...
Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates
Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a €20 million ($21.9 million) financing through the issuance of a Mandatory ...
Patanjali’s study on Renogrit, that fights cancer drug-induced kidney damage, among 2024’s most notable research papers
Patanjali’s Renogrit effectively mitigates kidney damage caused by the cancer drug cisplatin, according to a study published ...
CURE5d
SBRT May Offer Best Control Rates for Larger RCC Tumors, Study Finds
Among patients with renal cell carcinoma, those with larger tumors may yield the most benefit from SBRT compared with other ...
CURE3d
Fruzaqla Plus Sintilimab May Slow Renal Cell Carcinoma Progression
Fruzaqla given in combination with sintilimab slowed progression in the second line for those with locally advanced or metastatic renal cell carcinoma.
Hutchmed/Innovent update on Phase 2/3 study of Fruquintinib+Sintilimab
Hutchmed (HCM) and Innovent Biologics “jointly announce that the FRUSICA-2 Phase2/3 clinical trial evaluating fruquintinib in combination with ...
Hutchmed renal cell carcinoma trial meets primary endpoint
Hutchmed China, alongside Innovent Biologics, announced on Wednesday that the FRUSICA-2 phase two and three clinical trial ...